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Abstract
Background: To increase transparency in research, the International Committee of Medical Journal Editors required,
in 2005, prospective registration of clinical trials as a condition to publication. However, many trials remain unregistered
or retrospectively registered. We aimed to assess the association between trial prospective registration and treatment
effect estimates.
Methods: This is a meta-epidemiological study based on all Cochrane reviews published between March 2011 and
September 2014 with meta-analyses of a binary outcome including three or more randomised controlled trials published
after 2006. We extracted trial general characteristics and results from the Cochrane reviews. For each trial, we searched for
registration in the report’s full text, contacted the corresponding author if not reported and searched ClinicalTrials.gov and
the International Clinical Trials Registry Platform in case of no response. We classified each trial as prospectively registered
(i.e. registered before the start date); retrospectively registered, distinguishing trials registered before and after the primary
completion date; and not registered. Treatment effect estimates of prospectively registered and other trials were
compared by the ratio of odds ratio (ROR) (ROR <1 indicates larger effects in trials not prospectively registered).
Results: We identified 67 meta-analyses (322 trials). Overall, 225/322 trials (70 %) were registered, 74 (33 %) prospectively
and 142 (63 %) retrospectively; 88 were registered before the primary completion date and 54 after. Unregistered or
retrospectively registered trials tended to show larger treatment effect estimates than prospectively registered trials
(combined ROR = 0.81, 95 % CI 0.65–1.02, based on 32 contributing meta-analyses). Trials unregistered or registered after
the primary completion date tended to show larger treatment effect estimates than those registered before this date
(combined ROR = 0.84, 95 % CI 0.71–1.01, based on 43 contributing meta-analyses).
Conclusions: Lack of trial prospective registration may be associated with larger treatment effect estimates.
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Background
In 2005, the International Committee of Medical Journal
Editors (ICMJE) initiated a policy for trial registration to
increase transparency in research. All trials that started
recruiting on or after 1 July 2005 should be registered
prospectively (i.e. before participant enrolment) as a pre-
condition for publication in member journals [1]. Trials
that started recruitment before this date should be regis-
tered retrospectively but before 13 September 2005. The
World Health Organisation announced its support for
trial registration and launched the International Clinical
Trials Registry Platform (ICTRP) to facilitate access to
existing registries worldwide [2, 3]. These announcements
were followed by a massive increase in trial registration
that became the norm rather than the exception [3, 4].
However, a substantial proportion of trials remain unregis-
tered. A study published in 2009 found that 28 % of trials
published in the 10 general medical and specialty journals
with the highest impact factor were not registered [5].
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Another found that 39 % of published trials retrieved from
MEDLINE appeared not to have been registered [6].
Recently, some researchers generated an important de-
bate among the medical community, arguing that trials
published after 2010 that are not prospectively registered
should be excluded from Cochrane reviews [7]. Registra-
tion aims to make information about the existence and
methods of clinical trials publicly available to limit the
effect of selective publication of trials and outcomes with
positive results resulting in exaggerated treatment effect
estimates [8–13]. However, the evidence is as yet unclear
concerning a possible association between trial registra-
tion and treatment effect estimates [14].
In this study, we aimed to investigate whether there is
a difference in treatment effect estimates according to
trial prospective registration.
Methods
We performed a meta-epidemiological study. By using
large collections of meta-analyses, these studies are used
to assess the association between a trial characteristic
and treatment effect estimates [15–18]. For this study,
we focussed on Cochrane systematic reviews including
randomised controlled trials (RCTs) with results pub-
lished in 2006 or after. We chose 2006 because registra-
tion was required by the ICMJE from September 2005.
Data sources
We obtained data from all intervention systematic re-
views published between March 2011 and September
2014 from the Cochrane Collaboration. Data were pro-
vided as XML files and consisted of all elements entered
by the review authors in RevMan, the software developed
by the Cochrane Collaboration for preparing and maintain-
ing Cochrane reviews. Then, we applied the following selec-
tion criteria to perform the meta-epidemiological analyses.
Study selection
Identification of relevant systematic reviews
Using R 3.1.1 with the XML package, we automatically
identified all reviews of RCTs with meta-analyses of a
binary outcome including three or more RCTs published
after 2006. Reviews including observational studies were
not considered.
Selection of relevant meta-analyses
From the reviews identified, we manually screened all eli-
gible meta-analyses and selected those comparing an active
treatment to a placebo or no treatment. Comparisons of
two active interventions and meta-analyses of side effects
were excluded because of the uncertainty regarding the dir-
ection of the bias. If several meta-analyses were eligible per
review, we selected, whenever possible, the first meta-
analysis including at least four trials (three trials is the
minimum to perform meta-epidemiological analyses, four
trials allows more power). In case of overlapping meta-
analyses across reviews, defined as meta-analyses sharing
three or more trials, we selected the one with the largest
number of trials, and if they included the same number of
trials, we selected the most recent one.
Selection of trials
All trials included in the selected meta-analyses were in-
cluded in the study. RCTs without any events in both
arms did not contribute to the analysis.
Data available from Cochrane reviews
The following data were automatically extracted by using
R 3.1.1 with the XML package.
Review and meta-analysis characteristics
These characteristics included date of publication, medical
condition and, for the selected meta-analysis, interven-
tions being compared and outcome assessed.
Trial general characteristics and results
The general characteristics and results included the
following:
– Reference of the publication identified from the
ʻreferences to studies included in the review’.
– Risk of bias assessment: judgment of bias
(i.e. high, low or unclear risk of bias) for each
domain of the Cochrane Collaboration Risk of Bias
tool and the support for judgment. Because the
wording of domains may vary across reviews
(e.g. allocation concealment, allocation concealment
[selection bias], sequence concealment), we
pre-sorted all wording reported in the reviews and
manually classified them. According to the
Cochrane handbook, the blinding and incomplete
outcome data domains should be assessed at the
outcome level; therefore, for reviews reporting an
evaluation of these domains by outcome or type of
outcome, we manually identified the outcome
corresponding to the selected meta-analysis.
– Results: for each arm, the number of events as well
as the number of patients analysed.
Trial registration
Then, for each trial, we determined whether it was regis-
tered or not using the following sequential approach:
1. We manually searched the full text of each included
review for any information regarding registration
from the characteristics of included studies and the
domains of the Risk of Bias tool: ʻselective outcome
reporting’ and ʻother bias’.
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2. If no information was reported in the review, we
searched for the trial publication abstract and
screened whether a registration number was reported.
3. If no information was reported, we searched Google
for the publication title with key-words related to
registration (i.e. registration, ClinicalTrials.gov,
registered, NCT). If there was no result, we retrieved
and screened the full text of the publication.
4. For trials for which we were unable to find any
information regarding registration, we contacted the
corresponding author to ask whether the trial was
registered and, if so, in which registry and under
which number.
5. In case of no response from the author, two
reviewers independently searched ClinicalTrials.gov
and the ICTRP using the trial acronym, if any, and
keywords concerning population and experimental
intervention. All disagreements on trial matching
were resolved by consensus. A senior researcher
(AD) checked the matching between each trial
and registration information.
We classified each trial as (1) prospectively registered,
defined as registered before or within a month of the start
date (i.e. the date that enrolment to the protocol begins).
The ICMJE considers that registration should occur before
the start date, whereas the FDA considers that registration
should occur within 21 days after the start date. Our defin-
ition is in accordance with these statements and takes into
account the uncertainty regarding the exact start date, be-
cause for most trials, only month and year are reported;
(2) retrospectively registered, defined as registered more
than 1 month after the start date. We distinguished trials
registered before and after the primary completion date
(defined as the date of final collection of data for the pri-
mary outcome) because we made the assumption that
registration after primary completion date could be influ-
enced by the potential knowledge of the results and that it
could result in more bias; or (3) not registered.
We also classified trials by compliance with the ICMJE
requirements [2]. Trials starting before July 2005 were
considered compliant if they were registered before 13
September 2005 and trials starting in July 2005 or later
were considered compliant if they were prospectively
registered [2].
Statistical analysis
We estimated treatment outcomes as odds ratios (ORs).
Outcome events were re-coded so that an OR <1 indicated
a beneficial association with the experimental intervention.
To assess the association between registration and
treatment effect estimates, we compared treatment effect
estimates between:
1. Prospectively registered and other trials
(i.e. unregistered, retrospectively registered and
those for which this information was not reported)
which is defined as the primary analysis.
2. Trials registered before the primary completion
date and registered after or unregistered. Because
we had missing data on primary completion date
or completion date, we performed two different
analyses. In the first analysis, we considered trials for
which the primary completion date or completion
date was not reported as missing data and did not
take them into account in the analysis. In the second
analysis, we assumed that trials not reporting the
primary completion date were registered after the
primary completion date (worst-case scenario).
3. Trials compliant and not compliant with the ICMJE
requirement as defined above.
4. Registered and unregistered trials.
For each comparison, we used the following two-step
approach described by Sterne et al. [18]. First, for each
meta-analysis, we estimated a ratio of odds ratio (ROR) by
using a random-effects meta-regression. For the first
comparison, for example, this is the ratio of the OR in un-
registered or retrospectively registered RCTs to that in pro-
spectively registered RCTs. An ROR <1 indicates larger
treatment effect estimates for unregistered or retrospect-
ively registered than prospectively registered trials. Second,
we estimated a combined ROR across meta-analyses and
the 95 % CI by using a random-effects meta-analysis model.
The heterogeneity across meta-analyses was quantified with
the I2 statistic and the between–meta-analysis variance τ2.
All analyses involved the use of Stata SE 11.0 (StataCorp,
College Station, TX).
Results
Selection and characteristics of systematic reviews
The selection process is reported in Fig. 1. Briefly, from
2796 Cochrane reviews published between March 2011
and September 2014, 67 meta-analyses corresponded to
our inclusion criteria, for a total of 322 trials. The char-
acteristics of each meta-analysis are reported in the
Additional file 1. Briefly, the median number of trials in-
cluded per meta-analysis was 4 (Q1–Q3: 3–6), with a
maximum of 21 trials. The funding source was non-
profit in 154 trials (48 %), industry in 104 (32 %) and
both non- profit and industry in 22 (7 %).
Overall, 53 meta-analyses assessed a pharmacological
intervention for a total of 265 trials and 14 assessed a
non-pharmacological intervention for a total of 57 trials.
Registration of included trials
Information on trial registration was reported in the text
of the review for only 17 meta-analyses (25 %), including 7
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(10 %) for which this information was systematically re-
ported. Overall, 225/322 trials (70 %) were registered; the
median proportion of registered trials per meta-analysis
was 71 % (Q1–Q3: 55–100 %). Registration was prospect-
ive for 74 trials (33 %) and retrospective for 142 (63 %),
with 88 registered before the primary completion date and
54 after. The start date and/or primary completion date
was not reported for 9 (4 %) trials. Characteristics of
trials by registration status are listed in Table 1. Briefly,
among the 133 trials having started in July 2005 or
after, 69 (52 %) were prospectively registered, 29 (22 %)
were retrospectively registered but before the primary
completion date, 11 (8 %) were registered after the pri-
mary completion date, 2 were retrospectively registered
and did not report the primary completion date and 22
(17 %) were not registered. Thirty-six (23 %) of non-profit
trials were prospectively registered as compared with 35
(34 %) of industry-funded trials.
Fig. 1 Flow chart of the selection process. RCT, randomised controlled trial
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Comparison of treatment effect estimates between
prospectively registered and unregistered or
retrospectively registered trials
From 32 meta-analyses (165 trials), unregistered or
retrospectively registered trials tended to show larger
treatment effect estimates than prospectively registered
trials (combined ROR = 0.81, 95 % CI 0.65–1.02), with
low heterogeneity across meta-analyses, I2 = 21.6 % and
between–meta-analyses variance τ2 = 0.0767 (Fig. 2).
Comparison of treatment effect estimates between trials
registered before primary completion date and those
registered after or not registered
From 43 meta-analyses (213 RCTs), trials registered
after the primary completion date or unregistered tended
to show larger estimates than those registered before
(combined ROR= 0.84, 95 % CI 0.71–1.01), with low hete-
rogeneity across meta-analyses, I2 = 17.5 % and τ2 = 0.0516
(Fig. 3). A sensitivity analysis considering trials for which
the primary completion date was missing as trials registered
after the primary completion date gave consistent results
(ROR= 0.85, 95 % CI 0.72–1.01, I2 = 15.6 %, τ2 = 0.0449).
Comparison of treatment effect estimates between trials
compliant and not compliant with the ICMJE requirement
From 42 meta-analyses (207 RCTs), we found a combined
ROR= 0.86 (95 % CI 0.71–1.05) with larger estimates in tri-
als not compliant to the ICMJE requirement; heterogeneity
across meta-analyses was I2 = 36.6 %, τ2 = 0.1286 (Fig. 3).
Comparison of treatment effect estimates between
unregistered and registered trials
From 37 meta-analyses (177 trials), the combined ROR
between unregistered and registered trials was 0.85 (95 %
CI: 0.67–1.08) with I2 = 37.2 % and τ2 = 0.1591 (Fig. 3).
Discussion
With this study, we aimed to provide some evidence
concerning the association between trial registration and
treatment effect estimates. From a sample including all
Cochrane reviews with trials published in 2006 or after,
our results suggest that trials retrospectively registered
or not registered may show larger treatment effect esti-
mates than other trials. All analyses gave consistent results.














Pharmacological (N = 265) 66 (25) 72 (27) 46 (17) 7 (3) 74 (28)
Non-pharmacological (N = 57) 8 (14) 16 (28) 8 (14) 2 (4) 23 (40)
Publication yeara
2006–2009 (N = 169) 17 (10) 53 (31) 31 (18) 2 (1) 66 (39)
2010–2014 (N = 153) 57 (37) 35 (23) 23 (15) 7 (5) 31 (20)
Start datea
Before July 2005 (N = 162) 5 (3) 59 (36) 41 (25) 6 (4) 51 (31)
In July 2005 or after (N = 133) 69 (52) 29 (22) 11 (8) 2 (1) 22 (17)
Not reported (N = 27) 0 (0) 0 (0) 2 (7) 1 (4) 24 (89)
Sample size
Median (Q1–Q3) 242 (100–632) 152 (66–439) 153 (64–274) 97 (63–103) 87 (50–154)
Fundinga
Non-profit (N = 154) 36 (23) 50 (32) 29 (19) 4 (3) 35 (23)
Industry (N = 104) 35 (34) 31 (30) 19 (18) 4 (4) 15 (14)
Both (N = 22) 2 (9) 6 (27) 6 (27) 0 (0) 8 (37)
Not reported (N = 42) 1 (2) 1 (2) 0 (0) 1 (2) 39 (93)
Risk of bias
Sequence generation (high/unclear) 19 (26) 17 (19) 16 (30) 5 (56) 27 (28)
Allocation concealment (high/unclear) 25 (34) 26 (29) 21 (39) 6 (67) 47 (48)
Incomplete outcome data (high/unclear) 24 (34) 35 (40) 12 (22) 1 (11) 33 (34)
aPercentages are calculated by row
bPCD = primary completion date
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This is the first meta-epidemiological study assessing the
association between trial registration and treatment effects.
Meta-epidemiological studies are considered the gold stan-
dard for assessing bias [16]. To determine whether a trial
was registered, we used a sequential approach involving
contacting corresponding authors and a duplicate search of
registries in case of lack of information in trial reports. Be-
cause assessing the impact of prospective registration is
complex in that it became a requirement for trials starting
after July 2005, we conducted several complementary ana-
lyses (e.g. registration after the primary completion date,
compliance with the ICMJE requirement), all of which gave
consistent results with a trend to larger treatment effect
estimates for unregistered trials and those retrospectively
registered or registered after the primary completion date.
Two previous studies compared the conclusions of trials
by registration status in specific medical areas [19, 20].
One found that trials registered before publication and
those unregistered were equally likely to reach conclusions
favouring new oncology drugs [20]. A more recent study
found that trials in cardiology reported as registered were
less likely to report positive findings than those not re-
ported as registered [19]. Our results suggest that trial
registration is an important element to consider because it
may be associated with treatment effect estimates using
a meta-epidemiological approach. Results from meta-
Fig. 2 Comparison of treatment effect estimates between unregistered or retrospectively registered and prospectively registered trials. Difference
in treatment effect estimates is expressed as ratio of odds ratio (ROR). An ROR <1 indicates larger treatment effect estimates in trials retrospectively
registered or not registered
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epidemiological studies were used to determine the items
associated with treatment effect estimates that could be re-
lated to bias and served as a basis to develop the Cochrane
Risk of Bias tool [15, 16]. Meta-epidemiological studies have
identified other characteristics not directly associated
with a bias-producing process in an individual trial but
manifesting when looking at collections of trials. Such
characteristics including funding sources, single-centre sta-
tus or sample size have been considered meta-bias [21].
Trial registration may be another type of meta-bias.
Limitations
Our study has some limitations. To perform the meta-
epidemiological analysis, we had to predefine relatively re-
strictive selection criteria (i.e. selection of meta-analyses
involving three RCTs or more), which resulted in a limited
number of meta-analyses that may not be representative
of all Cochrane reviews. Our analyses may lack power and
we could only observe a trend but no statistically signifi-
cant results, so our results should be interpreted carefully.
We did not perform a formal sample size calculation be-
cause this is complex for meta-epidemiological studies
and because of the uncertainty regarding the amount of
difference in treatment effect estimates by registration sta-
tus [22]. We used all meta-analyses corresponding to our
eligibility criteria from our sample of Cochrane reviews
and reported the results transparently. We did not at-
tempt to increase our sample size a posteriori because this
would have been driven by our results. Such post hoc de-
cisions are criticised and may result in overestimated asso-
ciations. Even if we had found a statistical difference, we
think that this would not be sufficient to justify decisions
regarding the exclusion of trials from Cochrane reviews
based on their registration status. This rather highlights
the importance of systematically collecting this item and
performing sensitivity analyses when conducting meta-
analyses to assess whether it could affect the results. The
number of meta-analyses and the number of trials per
meta-analysis also limit the ability to explore whether
meta-confounding by trial funding sources, sample size
and risk of bias could explain our results because these
characteristics are frequently associated with treatment
effect estimates. Industry-sponsored trials are more likely
to comply with registration policies than non-profit-
funded trials [23–25] and also more likely to show
more favourable results [26]. Smaller trials or trials at
Fig. 3 Comparison of treatment effect estimates by trial registration. Difference in treatment effect estimates is expressed as ROR. An ROR <1 indicates
larger estimates of treatment effect in trials retrospectively registered or not registered, registered after the primary completion date, not compliant with
the ICMJE and not registered, respectively. * Compliance with the ICMJE requirement is defined as registration before 13 September 2005 for trials starting
before July 2005 and prospective registration for trials starting in July 2005 or after [2]. ICMJE International Committee of Medical Journal Editors
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high risk of bias might be more likely to be retrospectively
registered or unregistered. Nevertheless, it has to be noted
that most meta-epidemiological studies do not adjust on
possible confounding factors [27].
Implications
A first implication for future research is to confirm our
results in larger meta-epidemiological studies that could
also allow adjustment for important confounding factors
like funding source or sample size.
Other important implications can be discussed. Our
results remind us of the importance of prospective registra-
tion for all trials which should be systematically verified by
peer reviewers and editors during the peer review process.
We suggest a careful interpretation of trials not registered
or retrospectively registered, particularly those registered
after the primary completion date. At the systematic review
level, there is a need for systematically collecting and
reporting information on trial registration for each included
trial, which is currently not frequently done in systematic
reviews. Although it is recommended to systematically re-
port this information in reports of RCTs [28, 29], the
PRISMA Statement [30, 31] and the Cochrane Handbook
[16] do not contain recommendations for collecting and
reporting this information when conducting a systematic
review. Accounting for trial registration during the meta-
analysis process is challenging. Our results cannot allow for
recommending the exclusion of trials not registered or
retrospectively registered from meta-analyses. Nevertheless,
some arguments suggest that this approach is not appropri-
ate, as it may lead to the exclusion of more recent trials and
of trials funded by academic sources as they are less likely
than industry-funded trials to comply with registration
policy [23–25]. We rather recommend that review authors
conduct sensitivity analyses based on registration status to
check whether it has an influence on the results.
Conclusions
Our results suggest that trial registration may be associ-
ated with treatment effect estimates, with a tendency for
larger effects in unregistered or retrospectively registered
trials. Our results should be confirmed in other meta-
epidemiological studies but highlight the importance of
prospective registration for all trials.
Additional file
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